Welcome to our dedicated page for ALLURION TECHNOLOGIES SEC filings (Ticker: ALUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC filings for a medical-device pioneer can read like an FDA submission. With clinical-trial endpoints, digital-health KPIs, and reimbursement footnotes, finding what matters in Allurion Technologies鈥� disclosures is tough. Allurion Technologies SEC filings explained simply is exactly what investors search for, and it鈥檚 what Stock Titan delivers.
Open any document in our dashboard and you鈥檒l see AI-powered highlights that answer questions such as 鈥淲hat did R&D look like in the latest Allurion Technologies quarterly earnings report 10-Q filing?鈥� or 鈥淎re there new risk factors tied to balloon recalls?鈥� AG真人官方-time crawlers flag Allurion Technologies Form 4 insider transactions real-time, letting you review Allurion Technologies insider trading Form 4 transactions minutes after they hit EDGAR. Interactive charts pair with Allurion Technologies earnings report filing analysis so you can track margins, device placement volumes, and subscription revenue without wading through hundreds of pages. It鈥檚 all part of understanding Allurion Technologies SEC documents with AI.
In one visit you can scan an Allurion Technologies annual report 10-K simplified, drill into Allurion Technologies executive stock transactions Form 4, or preview an upcoming Allurion Technologies proxy statement executive compensation discussion. Sudden developments鈥攃linical study results, CE-mark milestones, or financing updates鈥攁rrive as Allurion Technologies 8-K material events explained in plain English. Whether you monitor insider buying ahead of pivotal trials or compare quarter-over-quarter unit growth, Stock Titan鈥檚 AI ensures you never miss a disclosure that could move the market.
Allurion Technologies, Inc. filed a Form 12b-25 notifying the SEC that its Form 10-Q for the quarter ended June 30, 2025 could not be filed on time. The notice identifies Brendan M. Gibbons, Chief Legal Officer as the contact and confirms that other periodic reports required over the prior 12 months have been filed. The company indicates it anticipates a significant change in results of operations for the period and includes customary forward-looking risk disclosures about potential adjustments to prior statements, regulatory or legal actions, possible delisting, and timing uncertainties related to completing and filing the 10-Q.
Allurion Technologies, Inc. disclosed accounting issues requiring correction and potential amendments to prior SEC reports, noting the company does not expect the corrections to affect reported revenue, gross margin, operating expenses, or cash. The filing flags risks including additional adjustments to prior statements, a delayed Q2 Quarterly Report for the period ended June 30, 2025, possible SEC or regulatory investigations, potential NYSE delisting, and shareholder litigation. The statement frames these as forward-looking risks while the company completes its evaluation.
Allurion Technologies said it issued a press release covering results for the three and six months ended June 30, 2025 and disclosed a potential accounting error. The company identified a likely miscalculation in non-cash items鈥�Other Comprehensive Income (Loss) and Other Income (Expense)鈥攔elated to the fair value of its Revenue Interest Financing Agreement (RIFA) and convertible notes, and believes correcting those calculations will likely require restating prior-period financial statements. The company stated these adjustments are non-cash and are not expected to affect revenue, gross margin, operating expenses, or cash. The press release is furnished as Exhibit 99.1.
FAQ
What is the current stock price of ALLURION TECHNOLOGIES (ALUR)?
What is the market cap of ALLURION TECHNOLOGIES (ALUR)?
